Efficacy and Safety of Ragweed SLIT-Tablet in Children with Allergic Rhinoconjunctivitis in a Randomized, Placebo-Controlled Trial
- PMID: 32304832
- DOI: 10.1016/j.jaip.2020.03.041
Efficacy and Safety of Ragweed SLIT-Tablet in Children with Allergic Rhinoconjunctivitis in a Randomized, Placebo-Controlled Trial
Abstract
Background: Ragweed sublingual immunotherapy (SLIT) tablet reduces symptoms and symptom-relieving medication use in adults with allergic rhinitis with or without conjunctivitis (AR/C) but has not been evaluated in children.
Objective: This international, multicenter, double-blind, placebo-controlled trial evaluated the efficacy and safety of ragweed SLIT-tablet in children with AR/C.
Methods: Children (N = 1025; 77.7% polysensitized) aged 5 to 17 years with ragweed pollen-induced AR/C with or without asthma (FEV1 ≥80% predicted) were randomized 1:1 to daily ragweed SLIT-tablet (12 Amb a 1-Unit) or placebo for up to 28 weeks (NCT02478398). The primary end point was the average total combined score (TCS; sum of rhinoconjunctivitis daily symptom score [DSS] and daily medication score [DMS]) during peak ragweed pollen season (RPS). Key secondary end points were TCS during the entire RPS, and DSS and DMS during the peak RPS.
Results: Relative TCS (95% CI) improvements with ragweed SLIT-tablet versus placebo were -38.3% (-46.0% to -29.7%; least square [LS] mean difference, -2.73; P < .001) during peak RPS and -32.4% (-40.7% to -23.3%; LS mean difference, -1.86; P < .001) during the entire RPS. DSS and DMS during peak RPS improved with SLIT-tablet versus placebo by -35.4% (-43.2% to -26.1%; LS mean difference, -1.40; P < .001) and -47.7% (-59.8% to -32.5%; LS mean difference, -1.84; P < .001), respectively. Asthma DSS, short-acting β-agonist use, and nocturnal awakenings during peak RPS improved with SLIT-tablet versus placebo by -30.7%, -68.1%, and -75.1%, respectively (all nominal P ≤ .02). No events of anaphylaxis, airway compromise, or severe treatment-related systemic allergic reactions were reported.
Conclusions: Ragweed SLIT-tablet significantly improved symptoms and decreased symptom-relieving medication use in children with ragweed pollen-induced AR/C and was well tolerated.
Keywords: Allergic rhinoconjunctivitis; Children; Ragweed; Sublingual immunotherapy.
Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Randomized controlled trial of ragweed sublingual immunotherapy tablet in the subpopulation of Canadian children and adolescents with allergic rhinoconjunctivitis.Allergy Asthma Clin Immunol. 2021 Dec 9;17(1):127. doi: 10.1186/s13223-021-00626-2. Allergy Asthma Clin Immunol. 2021. PMID: 34886880 Free PMC article.
-
Sublingual immunotherapy tablets in monosensitized and polysensitized adults with allergic rhinoconjunctivitis.Allergy Asthma Proc. 2024 Jan 1;45(1):33-36. doi: 10.2500/aap.2024.45.230068. Allergy Asthma Proc. 2024. PMID: 38151733 Clinical Trial.
-
The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial.J Allergy Clin Immunol. 2019 Mar;143(3):1058-1066.e6. doi: 10.1016/j.jaci.2018.12.1001. Epub 2019 Jan 15. J Allergy Clin Immunol. 2019. PMID: 30654054 Clinical Trial.
-
A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis.BMC Med. 2014 May 1;12:71. doi: 10.1186/1741-7015-12-71. BMC Med. 2014. PMID: 24885894 Free PMC article. Review.
-
The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases.Allergol Int. 2018 Jul;67(3):301-308. doi: 10.1016/j.alit.2018.03.008. Epub 2018 May 16. Allergol Int. 2018. PMID: 29759659 Review.
Cited by
-
Randomized controlled trial of ragweed sublingual immunotherapy tablet in the subpopulation of Canadian children and adolescents with allergic rhinoconjunctivitis.Allergy Asthma Clin Immunol. 2021 Dec 9;17(1):127. doi: 10.1186/s13223-021-00626-2. Allergy Asthma Clin Immunol. 2021. PMID: 34886880 Free PMC article.
-
The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children-A pivotal phase III trial.Allergy. 2025 Mar;80(3):795-806. doi: 10.1111/all.16363. Epub 2024 Nov 4. Allergy. 2025. PMID: 39495086 Free PMC article. Clinical Trial.
-
Malaysian Society of Allergy and Immunology Consensus Statement on Sublingual Immunotherapy in Allergic Rhinitis.J Clin Med. 2023 Feb 1;12(3):1151. doi: 10.3390/jcm12031151. J Clin Med. 2023. PMID: 36769797 Free PMC article. Review.
-
Allergen immunotherapy.Allergy Asthma Clin Immunol. 2024 Dec 16;20(Suppl 3):66. doi: 10.1186/s13223-024-00935-2. Allergy Asthma Clin Immunol. 2024. PMID: 39681846 Free PMC article. Review.
-
[Sensitization characteristics of ragweed pollen in Beijing area].Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2023 May;37(5):380-386. doi: 10.13201/j.issn.2096-7993.2023.05.012. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2023. PMID: 37138402 Free PMC article. Chinese.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials